Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages

Journal of Infectious Diseases

Volumn 191, Issue 1, 2005, Pages 127-137

  Monari, Claudia ^a   Bistoni, Francesco ^a   Casadevall, Arturo ^b   Pericolini, Eva ^a   Pietrella, Donatella ^a   Kozel, Thomas R ^c   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL RECEPTOR; CYTOKINE; FC RECEPTOR; GLUCURONOXYLOMANNAN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CELL SECRETION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT;

ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD86; CYTOKINES; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; I-KAPPA B PROTEINS; IMMUNOLOGIC FACTORS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; POLYSACCHARIDES; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11144275900     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/426511     Document Type: Article

References (23)

1. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8:515-48.
2. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-α release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001; 166:4620-6,
3. Murphy JW, Cozad GC. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun 1972; 5:896-901.
4. Retini C, Vecchiarelli A, Monari C, Bistoni F, Kozel TR. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun 1998; 66:664-9.
5. Syme RM, Bruno TF, Kozel TR, Mody CH. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect Immun 1999; 67:4620-7.
6. Murphy JW, Cox RA. Induction of antigen-specific suppression by circulating Cryptococcus neoformans antigen. Clin Exp Immunol 1988; 73:174-80.
7. Dong ZM, Murphy JW. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun 1995; 63:770-8.
8. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 1996; 64:2846-9.
9. Monari C, Retini C, Casadevall A, et al. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils. Eur J Immunol 2003; 33:1041-51.
10. Goldman D, Lee SC, Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun 1994; 62:4755-61.
11. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994; 38:580-7.
12. Mukherjee J, Feldmesser M, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob Agents Chemother 1995; 39:1398-405.
13. Cherniak R, Reiss E, Slodki ME, Plattner RD, Blumer SO. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol 1980; 17:1025-32.
14. Houpt DC, Pfrommer GS, Young BJ, Larson TA, Kozel TR. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect Immun 1994; 62:2857-64.
15. Plesner A, Greenbaum CJ, Lernmark A. Low serum conditions for in vitro generation of human macrophages with macrophage colony stimulating factor. J Immunol Methods 2001; 249:53-61.
16. Weiner SM, Bianco C, Nussenzweig V. Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood 1973; 42:939-46.
17. Pietrella D, Monari C, Retini C, Palazzetti B, Bistoni F, Vecchiarelli A. Human immunodeficiency virus type 1 envelope protein gp120 impairs intracellular antifungal mechanisms in human monocytes. J Infect Dis 1998; 177:347-54.
18. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20:309-21.
19. Mansour MK, Levitz SM. Interactions of fungi with phagocytes. Curr Opin Microbiol 2002; 5:359-65.
20. Dong ZM, Murphy JW. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun 1997; 65:557-63.
21. Syme RM, Spurrell JC, Amankwah EK, Green FH, Mody CH. Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcγ receptor II for presentation to T lymphocytes. Infect Immun 2002; 70:5972-81.
22. Kane LP, Lin J, Weiss A. It's all Rel-ative: NF-κB and CD28 costimulation of T-cell activation. Trends Immunol 2002; 23:413-20.
23. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr Opin Immunol 1999; 11: 294-300.